Mirion Technologies, Inc. (MIR): one to watch?

Sold off on soft organic growth/Medical segment despite an EPS beat and reaffirmed guidance — not a fundamental breakdown, but not a screaming bargain either.

👀 WATCH Fundamentals57/100

Fell 13% in 1 trading day(s) — now $14.57

Why MIR dropped

Mirion beat Q2 EPS estimates ($0.12 vs $0.11 expected) and reaffirmed full-year guidance, but revenue came in slightly below consensus and investors focused on weak organic growth and a softer Medical segment, sending the stock down 13% the next day on heavy volume.

Fwd P/E 22.3Op margin 6.7%Rev growth 19.7%Debt/equity 65.8%Analyst upside 88.1%

How this scored 57/100

✅ Passes all 4 hard checks — profitable, cash-generative, and financially survivable.

✅ Makes money Net profit margin 2.4%

✅ Generates cash Free cash flow $108M

✅ Not drowning in debt Debt/equity 65.8% (limit 200%)

✅ Can pay its bills Current ratio 3.2 (needs 1+)

Bar length shows how much each metric is worth — a 10-point metric is twice as wide as a 5-point one. Hover any row for what it means.

Profitability Does it actually make money? 3/25

Operating margin 6.7% 2/9

Net profit margin 2.4% 1/8

Return on equity 1.5% 0/8

Growth Is it getting bigger, or dying? 17/25

Revenue growth 19.7% 7/9

Earnings growth 0.0% 2/8

Expected profit change 627.0% 8/8

Value Is it cheap right now? 15/25

Forward P/E 22.3 6/10

PEG ratio unknown 2/8

Analyst target upside 88.1% 7/7

Balance sheet Will it survive? 22/25

Debt / equity 65.8% 7/10

Current ratio 3.2 8/8

Free cash flow $108M 7/7

🔒 Read the full AI analysis

Create a free account to unlock the bull case and the risks for MIR — plus today's other picks.

Analysis generated by SmartStonks's AI from public fundamentals and news, first flagged 2026-07-30. Research only — not financial advice.